



CRITERIA FOR VALIDATION OF ELIMINATION OF VIRAL HEPATITIS B AND C: REPORT OF SEVEN COUNTRY PILOTS

CRITERIA FOR VALIDATION OF ELIMINATION OF VIRAL HEPATITIS B AND C: REPORT OF SEVEN COUNTRY PILOTS

Criteria for validation of elimination of viral hepatitis B and C: report of seven country pilots

ISBN 978-92-4-005529-2 (electronic version)

ISBN 978-92-4-005530-8 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Criteria for validation of elimination of viral hepatitis B and C: report of seven country pilots. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

Acknowledgements	iv
Abbreviations	v
1. Background	1
2. Objectives of country pilots of WHO criteria for country validation of viral hepatitis elimination	4
3. Methodology	4
4. Key findings and lessons learned from the elimination pilots	5
4.1. Criteria for validation of elimination of mother-to-child transmission of hepatitis....	5
4.1.1. Key findings	5
4.1.2. Lessons learned: criteria for validation of elimination of mother-to-child transmission of HBV	8
4.2. Criteria for assessment of reduction in hepatitis C incidence	9
4.2.1. Key findings	9
4.2.2. Lessons learned: criteria for assessment of reduction in incidence of hepatitis C infection	12
4.3.1. Key findings	13
4.3.2. Lessons learned: HBV- and HCV-specific mortality criteria	15
4.4. Country feedback on validation criteria, tools and processes	16
4.4.1. Key findings	16
4.4.2. Lessons learned: country findings and feedback on validation criteria, tools and processes	16
5. Five key considerations and next steps	17
References	19
Annex. Key data inputs and hepatitis elimination profiles from the seven participating pilot countries	20

ACKNOWLEDGEMENTS

Acknowledgements are due to the many experts who contributed to the elimination pilots and /or development of this report.

Special thanks are due to the ministries of health and partners in the countries concerned. **Brazil:** Ana Cristina Garcia Ferreira and Karen Cristine Tonini (Ministry of Health); and Glaucio Junior (National Viral Hepatitis Program); **Egypt:** Mohamad Hassany (National Hepatology and Tropical Medicine Research Institute, Ministry of Health); Mohamed AbdAllah, Wael Abdel-Razek, Dina Ahmed, Noha Asem, Shaimaa Abdel Aziz, Ihab Basha, Nancy El Guindy, Heba Elsayed, Tamer Essam, Alaa Abdel Fattah, Ramy Galal, Mahmoud Ghazali, Amr Kandeel, Mona Khalifa, Rofida Mahmoud, Kadry Mohamed, Marwa Mohsen, Anas Mostafa, Amal Naguib, Tarek Saad, Heba Said, Aysam Salah, Ehab Serag, Shaimaa Shawky and Omnia Tantawi; **Georgia:** Ekaterine Adamia, Zurab Azarashvili and Tamar Gabunia (Ministry of Internally Displaced Persons from the Occupied Territories, Labor, Health and Social Affairs); Amiran Gamkrelidze (National Center for Disease Control and Public Health); and Maia Alkhazashvili, Davit Baliashvili, Ketevan Galdavadze, Vladimir Geti, Lia Javidze, Levan Kandelaki, Tsira Merabishvili, Ketevan Stvilia, Maia Tsereteli and Irina Tskhomelidze (Training Programs in Epidemiology and Public Health Interventions Network); **Mongolia:** Bayarbold Dangaa and Amarzaya Sarankhuu (Ministry of Health); and Badral Davgasuren (Department of Communicable Diseases Surveillance and Research, National Center for Communicable Diseases); **Rwanda:** Gallican Rwibasira (Ministry of Health); Janvier Serumondo (Hepatitis Programme, Rwanda Biomedical Centre); and Eric Seruyange (Rwanda Military Hospital and College of Medicine and Health Sciences, University of Rwanda); **Thailand:** Suchada Jiamsiri (Ministry of Health); and Montinee Vasantiuppapokakorn (Division of AIDS and STIs, Department of Disease Control, Ministry of Public Health); **United Kingdom**

of Great Britain and Northern Ireland: Beatrice Emmanouil, Graham Foster and Mark Gillyon-Powell (National Health Service, England); Monica Desai, David Leeman and Sema Mandal (UK Health Security Agency).

Thanks are also due to Paige Armstrong, Nino Khetsuriani, Rania Tohme and Carolyn Wester (United States Centers for Disease Control and Prevention, Atlanta, GA, United States of America (USA)).

WHO staff from the following offices also contributed to this report: **International Agency for Research on Cancer** (Early Detection, Prevention and Infections Branch, Lyon, France): Catherine de Martel; **WHO headquarters** (Global HIV, Hepatitis and STIs Programmes, Geneva, Switzerland): Meg Doherty, Philippa Easterbrook, Diana Faini, Olufunmilayo Lesi, Daniel Low-Beer, Maura Laverty, Niklas Luhmann, Morkor Newman Owiredu and Caitlin Quinn; **WHO African Region:** Casimir Manzengo Mingiedi (WHO Regional Office for Africa, Brazzaville, Congo) and Jules Mugabo Semahore (WHO Country Office for Rwanda); **WHO Region of the Americas:** Leandro Sereno (WHO Regional Office for the Americas, Washington, DC, USA); **WHO South-East Asia Region:** Deyer Gopinath (WHO Country Office for Thailand) and B.B. Rewari (WHO Regional Office for South-East Asia, New Delhi, India); **WHO European Region:** Nino Mamulashvili (WHO Country Office for Georgia) and Antons Mozalevskis (WHO Regional Office for Europe, Copenhagen, Denmark); **WHO Eastern Mediterranean Region:** Naeema H. Al Gasseer, Samah Bastawy, Noha El Qareh, Nahla Gamaleldin, Quamrul Hasan, Alaa Hashish, Yvan Hutin, Bridget Akora Mugisa and Ahmed Alaama Sabry (WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt); **WHO Western Pacific Region:** Munkhjargal Ayurzana (WHO Country Office for Mongolia) and Po-Lin Chan (WHO Regional Office for the Western Pacific, Manila, Philippines).

ABBREVIATIONS

Ab	antibody
ANC	antenatal care
CI	confidence interval
DAA	direct-acting antiviral (drug)
EASL	European Association for the Study of the Liver
ECDC	European Centre for Disease Prevention and Control
EMTCT	elimination of mother-to-child transmission
EPI	Expanded Programme on Immunization
GFME	Global Framework for Multi-disease Elimination
GHSS	Global health sector strategy on viral hepatitis 2016–2021
GVAC	Global Validation Advisory Committee
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
HepB-BD	hepatitis B vaccine birth dose (HepB-BD)
HIV	human immunodeficiency virus
M&E	monitoring and evaluation
MTCT	mother-to-child transmission
OST	opioid substitution therapy
PMTCT	prevention of mother-to-child transmission
PTE	Path to Elimination
PVST	post-vaccination serology testing
PWID	people who inject drugs
UAM	unlinked anonymous monitoring (survey)
UNICEF	United Nations Children’s Fund
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31665

